BCM
ELVN icon

Boxer Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Boxer Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-671,358
Closed -$13.2M – 25
2025
Q1 		$13.2M Hold
671,358
– – 3.97% 11
2024
Q4 		$15.1M Buy
+671,358
New +$17.4M 1.29% 23

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Boxer Capital Management's ELVN Position: Q2 2025 in Review

Boxer Capital Management sold out of Enliven Therapeutics (ELVN) in Q2 2025, closing a stake of 671,358 shares — an estimated $13.2M sold.

Boxer Capital Management first reported a position in ELVN in Q4 2024 and held it in 2 quarters. The position peaked at $15.1M in Q4 2024. 124 funds tracked by Wall St. Rank hold ELVN as of Q2 2025.

  • Boxer Capital Management reported no remaining Enliven Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Boxer Capital Management sold 671,358 Enliven Therapeutics shares in Q2 2025, an estimated $13.2M.
  • Boxer Capital Management first reported a position in Enliven Therapeutics in Q4 2024 and held it in 2 quarters.
  • Boxer Capital Management's Enliven Therapeutics position peaked at $15.1M in Q4 2024.
  • 124 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2025.

Based on Boxer Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.